Viewing Study NCT06616259


Ignite Creation Date: 2025-12-24 @ 2:52 PM
Ignite Modification Date: 2026-02-21 @ 2:03 PM
Study NCT ID: NCT06616259
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-09-27
First Post: 2024-09-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
Sponsor: Meng Qiu
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module